Literature DB >> 11061605

Effect of single chemotherapeutic agents on the growing skeleton of the rat.

B L van Leeuwen1, W A Kamps, R M Hartel, R P Veth, W J Sluiter, H J Hoekstra.   

Abstract

BACKGROUND: To establish the effect of chemotherapeutics on the growing skeleton, male Wistar rats were studied.
DESIGN: Between the ages of 4 and 13 weeks the rats were given i.v. doxorubicin 15 mg/m2 body surface area (BSA), methotrexate 60 mg/m2 BSA or cisplatin 7.5 mg/m2 BSA. For each group of drug-treated rats there was a diet-matched control group that was injected with a placebo only. Rats fed ad libitum served as the basic control group for length and weight growth. Body weight and tibial length were measured weekly. Kidney and liver weight were determined at the end of the study.
RESULTS: Weight gain and length growth were significantly decreased in the diet controlled groups (P < 0.05). Doxorubicin reduced length growth with 4.12 mm or 18% (P < 0.05). Methotrexate reduced length growth with 1.11 mm or 5% (P < 0.05). Length growth in the cisplatin treated rats did not differ from the diet controls.
CONCLUSIONS: Doxorubicin and methotrexate decrease length growth in the rat tibia by, respectively, 18% and 5%. Cisplatin does not affect length growth. The decrease in growth might be a direct effect of doxorubicin and methotrexate on the tibial growth plate and metaphysis, but may be more pronounced due to the malnutrition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061605     DOI: 10.1023/a:1008352620870

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  9 in total

1.  Osteopontin promoter polymorphisms at locus -443 are associated with metastasis and poor prognosis of human intrahepatic cholangiocarcinoma in Chinese population.

Authors:  Xiang-Qian Zhao; Huan-Xian Ma; Mao-Sheng Su; Lei He
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 2.  Does Systemic Chemotherapy Influence Skeletal Growth of Young Osteosarcoma Patients as a Treatment-Related Late Adverse Effect?

Authors:  Manabu Hoshi; Naoto Oebisu; Tadashi Iwai; Yoshitaka Ban; Hiroaki Nakamura
Journal:  Curr Oncol       Date:  2022-06-04       Impact factor: 3.109

3.  Paley's multiplier method does not accurately predict adult height in children with bone sarcoma.

Authors:  Magdalena Maria Gilg; Christine Wibmer; Dimosthenis Andreou; Alexander Avian; Petra Sovinz; Werner Maurer-Ertl; Per-Ulf Tunn; Andreas Leithner
Journal:  Clin Orthop Relat Res       Date:  2014-04-29       Impact factor: 4.176

Review 4.  Bone metastasis: the importance of the neighbourhood.

Authors:  Peter I Croucher; Michelle M McDonald; T John Martin
Journal:  Nat Rev Cancer       Date:  2016-05-25       Impact factor: 60.716

5.  Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific.

Authors:  Gonçalo C Pereira; Susana P Pereira; Claudia V Pereira; José A Lumini; José Magalhães; António Ascensão; Maria S Santos; António J Moreno; Paulo J Oliveira
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

Review 6.  Methotrexate toxicity in growing long bones of young rats: a model for studying cancer chemotherapy-induced bone growth defects in children.

Authors:  Chiaming Fan; Kristen R Georgiou; Tristan J King; Cory J Xian
Journal:  J Biomed Biotechnol       Date:  2011-03-17

7.  Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFβ.

Authors:  Tapasi Rana; Anwesa Chakrabarti; Michael Freeman; Swati Biswas
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

8.  Gαq protein carboxyl terminus imitation polypeptide GCIP-27 improves cardiac function in chronic heart failure rats.

Authors:  Xiao Lan Lu; Yang Fei Tong; Ya Liu; Ya Li Xu; Hua Yang; Guo Yuan Zhang; Xiao-Hui Li; Hai-Gang Zhang
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

9.  Reversal of Doxorubicin-Induced Bone Loss and Mineralization by Supplementation of Resveratrol and MitoTEMPO in the Early Development of Sparus aurata.

Authors:  Sunil Poudel; Marisol Izquierdo; Maria Leonor Cancela; Paulo J Gavaia
Journal:  Nutrients       Date:  2022-03-09       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.